- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01082705
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children
Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months
Following the rapid development of significant drug resistance to both chloroquine and sulfadoxine-pyrimethamine (the first line therapy in Tanzania from 2001 -2006), artemether- lumefantrine (Coartem or AL) was adopted as first line therapy in Tanzania in 2006. Now that this drug has been widely used for some time, the investigators propose to conduct an antimalarial efficacy trial to monitor the effectiveness of this therapy, to determine if this drug remains efficacious, or if significant resistance has emerged, in which case a new antimalarial strategy will need to be contemplated. The investigators hypothesize that the efficacy of Artemether-lumefantrine remains high, and that the other artemisinin combination therapies will be equally efficacious.
Children 6-59 months of age with symptomatic malaria will be randomly assigned to be treated with either artemether + lumefantrine (Coartem) or dihydroartemisinin-piperaquine (Duo-Cotecxin or Artekin). Clinical, parasitologic, and hematologic parameters will be monitored over a 42-day follow-up period and will be used to evaluate drug efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bagamoyo, Tanzania
- Miono Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6-59 months
- Axillary temperature ≥ 37.5º C or history of fever in the past 48 hours
- Weight ≥ 5.0 kg
- Slide-confirmed infection with P. falciparum, with parasitemia 2,000-200,000 asexual forms per μl
- Live within the boundaries of the officially recognized catchment area of Miono Health Center.
- Caregiver agrees to all blood draws and return visits.
Exclusion Criteria:
- General danger signs or symptoms of severe malaria
- Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean (National Center for Health Statistics [NCHS]/World Health Organization [WHO] normalized reference values)
- Slide confirmed infection with any other Plasmodium spp. besides falciparum or mixed plasmodium infection
- Severe anemia, defined as Hb < 5 g/dl
- Known hypersensitivity to any of the drugs being tested
- Presence of febrile conditions caused by diseases other than malaria
- Serious or chronic medical condition (heart failure, sickle cell disease).
- Plan to travel or leave the area within the next 3 months.
- Have been treated for malaria in the 2 weeks prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Artemether-lumefantrine
Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
|
administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
Other Names:
|
Experimental: Dihydroartemisinin-piperaquine
Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
|
once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
42-day polymerase chain reaction (PCR)-adjusted parasitological cure of P. falciparum parasitemia
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hematologic response to treatment measured as mean change in hemoglobin concentration from Day 0 to Day 42
Time Frame: 42 days
|
42 days
|
Collaborators and Investigators
Investigators
- Study Director: Julie R Gutman, MD MSc, Centers for Disease Control and Prevention
- Principal Investigator: S. Patrick Kachur, MD MPH, Centers for Disease Control and Prevention
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMPACT TZ IV2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on P. Falciparum Malaria
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteCompletedP. Falciparum Malaria | P. Falciparum Malaria Mixed InfectionThailand
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
Universidad Nacional de ColombiaSanofi Pasteur, a Sanofi CompanyCompleted
-
Radboud University Medical CenterCompletedP. Falciparum MalariaNetherlands
-
Novartis PharmaceuticalsCompletedAcute Uncomplicated P. Falciparum Malaria
-
University of OxfordWorld Health OrganizationCompleted
-
Centre MurazInstitute of Tropical Medicine, BelgiumCompletedUncomplicated P. Falciparum Malaria in ChildrenBurkina Faso
-
University of North Carolina, Chapel HillDoris Duke Charitable FoundationRecruitingMalaria | P. FalciparumUganda
-
Barcelona Institute for Global HealthCompletedP. Falciparum
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
Clinical Trials on artemether-lumefantrine
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
University of OxfordUniversity of KinshasaCompleted
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRecruitingHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda
-
Novartis PharmaceuticalsCenters for Disease Control and PreventionCompletedMalariaUnited States
-
NovartisCompletedMalaria | FalciparumBenin, Kenya, Mali, Mozambique, Tanzania
-
Centers for Disease Control and PreventionIfakara Health Research and Development CentreCompleted